Janux Therapeutics Inc (JANX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $695.65M
Last updated: Nov 17, 2026 at 11:06 AM ET
Janux Therapeutics Inc (JANX) Competitors
The companies most similar to Janux Therapeutics are Nuvectis Pharma (NVCT), Syndax Pharmaceuticals (SNDX) and CytomX Therapeutics (CTMX). By market cap, Janux Therapeutics ranks 9th of the 13 companies on this page; Ultragenyx (RARE) is the largest at $1.64B.
Peer Comparison
JANX's revenue growth of -7.1% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Janux Therapeutics (JANX) | $695.65M | N/A | 29.6x | 0.0% | N/A | -7.1% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Syndax Pharmaceuticals Inc (SNDX) | $850.77M | N/A | 2.8x | -72.3% | -65.0% | 81.6% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Annexon Inc (ANNX) | $747.79M | N/A | N/A | 0.0% | -84.6% | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Ardelyx Inc (ARDX) | $776.74M | N/A | 1.6x | -11.8% | -6.5% | 15.7% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Peer median | $730.85M | 95.1x | 8.0x | 0.0% | -65.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Janux Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Syndax Pharmaceuticals Inc (SNDX) | Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. | SNDX competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Annexon Inc (ANNX) | Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. | ANNX competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
| Ardelyx Inc (ARDX) | Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States... | ARDX competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| Immatics NV (IMTX) | Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies... | IMTX competitors |
Frequently Asked Questions About JANX
Who are Janux Therapeutics' main competitors?
The companies most similar to Janux Therapeutics include Nuvectis Pharma (NVCT), Syndax Pharmaceuticals (SNDX), CytomX Therapeutics (CTMX), Annexon (ANNX) and Theravance Biopharma (TBPH), listed from the closest match.
Who is Janux Therapeutics' biggest competitor?
Ultragenyx (RARE) is the largest of the similar companies at $1.64B; Nuvectis Pharma (NVCT) is the closest match by business profile, size, sector and industry.
How does JANX stock compare with its competitors?
JANX's P/S is 29.6x against a peer median of 8.0x; its net margin is 0.0% against a peer median of 0.0%.
Which of Janux Therapeutics' competitors pays a higher dividend?
Janux Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Janux Therapeutics bigger than its competitors?
No. Janux Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Ultragenyx (RARE) at $1.64B.
JANX pages: Overview, Earnings, Forecast, Financials, Competitors